FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2317266312> ?p ?o ?g. }

• W2317266312 endingPage "2024" @default.
• W2317266312 startingPage "2024" @default.
• W2317266312 abstract "2024 Background: Bevacizumab (BEV) improves outcome in a subset of patients with recurrent glioblastoma (GBM). Identification of this subset would improve patient selection for BEV therapy. The observation that BEV treatment induces diffusion weighted imaging (DWI) changes in some patients led to this study evaluating the relationship of DWI and apparent diffusion coefficient (ADC) to clinical outcome in recurrent GBM patients receiving BEV. Methods: We reviewed clinical data and brain MRIs of 262 adults with recurrent GBM treated with BEV. Patients with relevant imaging studies (MRI with DWI and ADC) at pretreatment baseline and at least 1 follow-up were categorized based on presence of DWI hyperintensity (DWI-HI) at baseline. Each group was subdivided based on the presence or absence of low ADC signal. The overall survival (OS) and progression free survival (PFS) rates were analyzed using the Kaplan Meier method and the log rank test. Results: Of 191 evaluable patients, 107 had new or increased DWI-HI after BEV. Patients with low ADC (n = 46) had a statistically significant improvement over those without low ADC (n = 61) in PFS (median 249 vs. 130 days; p = 0.0024; HR = 0.5) and OS (median 425 vs. 232 days; p < 0.0001; HR = 0.34). Of 60 patients with baseline DWI-HI which increased after BEV, patients with low ADC (n = 25) had better PFS and OS compared with those who did not (n = 35) (median PFS 218 vs. 97days; p = 0.0035, HR = 0.4; median OS 382 vs. 205 days; p = 0.0002; HR = 0.27). 47 patients developed DWI-HI after BEV; those with low ADC showed statistically significant improvement in OS but not PFS. Conclusions: Patients with a diffusion restricted (“ischemic”) MRI phenotype which appears or increases upon BEV treatment have improved PFS and OS compared with those without such changes, indicating a potential for using DWI to predict clinical outcome with BEV treatment in patients with recurrent GBM. A prospective study is being developed to better characterize the implications of these results. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Bayer, Genentech, Merck, Novartis, Pfizer, Schering-Plough IMEDEX, Merck, Novartis, Schering-Plough Celgene, Genentech, Lilly, MGI Pharma, Novartis, Pfizer, Schering-Plough" @default.
• W2317266312 created "2016-06-24" @default.
• W2317266312 creator A5001098802 @default.
• W2317266312 creator A5036347055 @default.
• W2317266312 creator A5058672778 @default.
• W2317266312 creator A5064048609 @default.
• W2317266312 creator A5072892351 @default.
• W2317266312 date "2010-05-20" @default.
• W2317266312 modified "2023-09-26" @default.
• W2317266312 title "Diffusion restriction as a predictor of response in recurrent glioblastoma patients receiving bevacizumab." @default.
• W2317266312 doi "https://doi.org/10.1200/jco.2010.28.15_suppl.2024" @default.
• W2317266312 hasPublicationYear "2010" @default.
• W2317266312 type Work @default.
• W2317266312 sameAs 2317266312 @default.
• W2317266312 citedByCount "2" @default.
• W2317266312 countsByYear W23172663122012 @default.
• W2317266312 crossrefType "journal-article" @default.
• W2317266312 hasAuthorship W2317266312A5001098802 @default.
• W2317266312 hasAuthorship W2317266312A5036347055 @default.
• W2317266312 hasAuthorship W2317266312A5058672778 @default.
• W2317266312 hasAuthorship W2317266312A5064048609 @default.
• W2317266312 hasAuthorship W2317266312A5072892351 @default.
• W2317266312 hasConcept C126322002 @default.
• W2317266312 hasConcept C126838900 @default.
• W2317266312 hasConcept C143409427 @default.
• W2317266312 hasConcept C143998085 @default.
• W2317266312 hasConcept C149550507 @default.
• W2317266312 hasConcept C2776194525 @default.
• W2317266312 hasConcept C2776694085 @default.
• W2317266312 hasConcept C2777802072 @default.
• W2317266312 hasConcept C2780739268 @default.
• W2317266312 hasConcept C2989005 @default.
• W2317266312 hasConcept C3019894029 @default.
• W2317266312 hasConcept C502942594 @default.
• W2317266312 hasConcept C70816921 @default.
• W2317266312 hasConcept C71924100 @default.
• W2317266312 hasConceptScore W2317266312C126322002 @default.
• W2317266312 hasConceptScore W2317266312C126838900 @default.
• W2317266312 hasConceptScore W2317266312C143409427 @default.
• W2317266312 hasConceptScore W2317266312C143998085 @default.
• W2317266312 hasConceptScore W2317266312C149550507 @default.
• W2317266312 hasConceptScore W2317266312C2776194525 @default.
• W2317266312 hasConceptScore W2317266312C2776694085 @default.
• W2317266312 hasConceptScore W2317266312C2777802072 @default.
• W2317266312 hasConceptScore W2317266312C2780739268 @default.
• W2317266312 hasConceptScore W2317266312C2989005 @default.
• W2317266312 hasConceptScore W2317266312C3019894029 @default.
• W2317266312 hasConceptScore W2317266312C502942594 @default.
• W2317266312 hasConceptScore W2317266312C70816921 @default.
• W2317266312 hasConceptScore W2317266312C71924100 @default.
• W2317266312 hasIssue "15_suppl" @default.
• W2317266312 hasLocation W23172663121 @default.
• W2317266312 hasOpenAccess W2317266312 @default.
• W2317266312 hasPrimaryLocation W23172663121 @default.
• W2317266312 hasRelatedWork W2013603514 @default.
• W2317266312 hasRelatedWork W2015819871 @default.
• W2317266312 hasRelatedWork W2040260938 @default.
• W2317266312 hasRelatedWork W2308980749 @default.
• W2317266312 hasRelatedWork W2735229934 @default.
• W2317266312 hasRelatedWork W2933320214 @default.
• W2317266312 hasRelatedWork W2942024685 @default.
• W2317266312 hasRelatedWork W2944702521 @default.
• W2317266312 hasRelatedWork W2966975937 @default.
• W2317266312 hasRelatedWork W3117648193 @default.
• W2317266312 hasVolume "28" @default.
• W2317266312 isParatext "false" @default.
• W2317266312 isRetracted "false" @default.
• W2317266312 magId "2317266312" @default.
• W2317266312 workType "article" @default.